Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a report released on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Price Performance

Shares of CYCC opened at $1.32 on Tuesday. The company has a 50-day simple moving average of $1.06 and a two-hundred day simple moving average of $1.58. The firm has a market capitalization of $2.84 million, a PE ratio of -0.08 and a beta of 0.51. Cyclacel Pharmaceuticals has a one year low of $0.75 and a one year high of $10.12.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.11. Cyclacel Pharmaceuticals had a negative return on equity of 1,901.11% and a negative net margin of 21,963.75%. During the same period in the previous year, the firm posted ($6.60) earnings per share. Analysts expect that Cyclacel Pharmaceuticals will post -2.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Cyclacel Pharmaceuticals

An institutional investor recently bought a new position in Cyclacel Pharmaceuticals stock. Armistice Capital LLC purchased a new position in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned about 9.18% of Cyclacel Pharmaceuticals as of its most recent SEC filing. 23.58% of the stock is owned by institutional investors and hedge funds.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.